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O
n a Friday night 
in March 2009, 
I joined more 
than 30 doc-
tors gathered 
at the Gleneagles Hotel 
for predinner drinks. We 
were attending a weekend 
meeting at the invitation of 
the University of Dundee’s 
Hypertension Research 
Centre and Medicines 
Monitoring Unit after “pos-
itive feedback” from a sim-
ilar gathering in  January. 
Both meetings aimed to 
provide practices with suf-
ficient information about 
the Standard Care versus 
Celecoxib Outcome Trial 
(SCOT) to enable general 
practitioners to decide 
whether to participate.
The invitation did not 
mention Pfizer, although 
the drug company was 
providing £26m (€30m; 
$43m) for the study.1 
Instead, the trial was 
described as “an academic, investigator-
initiated study, requested by the European 
Medicines Agency (EMEA) and sponsored 
by the University of Dundee.” The university 
is working in partnership with the universi-
ties of Glasgow, Edinburgh, and Aberdeen 
and collaborating with researchers from 
Nottingham University and the  University 
of Southern Denmark.2 3
The SCOT application form submitted to 
the NHS research ethics committee indicates 
that Pfizer is the sole funder of the study.
The trial is designed to compare the car-
diovascular safety of the cyclo-oxygenase-2 
(COX-2) inhibitor celecoxib with that of 
other non-steroidal anti-inflammatory drugs 
(NSAID) in men and women who are over 
60, who already take a non-selective NSAID 
regularly, and who do not have established 
cardiovascular or peripheral vascular disease 
or severe heart failure.3
Recruitment started in February 2008 and 
is expected to last three years with a total of 
16 000 patients.1 Dundee University plans to 
increase the number of participants by run-
ning the trial in England and another Euro-
pean country, possibly the Netherlands.
After hearing about the meeting and 
approaching the university for comment, 
I received a call from Beattie Communica-
tions, the public relations firm that is manag-
ing the trial and which lists Pfizer as one of 
its  clients,4 and was invited to attend by the 
chief investigator.
Doctors attending the information meeting, 
which started at 9 am on Saturday and ended 
with a three course lunch, had complimentary 
drinks and dinner the night before, accom-
modation at the five star luxury hotel on the 
Friday night, and their travel reimbursed.
The principal investigator, Tom 
 MacDonald, said that attendees received 
only “standard set menus and 
no excessive hospitality was 
given.” He also stressed “GPs 
had given up their Saturday 
without pay to be trained in 
trial  methodology.”
The educational meeting 
at Gleneagles was a cost cut-
ting measure, according to 
 Professor MacDonald: “We 
found that if we rented out 
a room somewhere during 
the week, doctors weren’t 
coming. But they are com-
ing if we set up meetings at 
the weekend at Gleneagles. 
This still works out better for 
us. The whole deal we get 
from the hotel is a lot less 
than £300. You could say 
the recession’s helped us do 
the study.”
His argument is that doc-
tors have to be paid a locum 
fee of £350 a day if these 
meetings are held during the 
week and one partner would 
have to leave the surgery.
Thir ty  f ive  doctors 
attended the meeting from 25 practices. Up 
to four GPs were in attendance from a sin-
gle practice. Some doctors said their prac-
tice had already signed up to the trial. One 
of them admitted coming along just for the 
hospitality. Another joked, “If we don’t sign 
up now, does that mean we get to come to 
Gleneagles again and again until we make 
our minds up?”
Practices that sign up get £1000 and a fur-
ther £5 every two months for each patient 
reporting progress on a web portal. Professor 
MacDonald said: “Some practices have more 
than 50 patients. That’s quite a lot of money, 
but it goes to the practice. Dundee University 
does not sign any cheques for doctors.”
The chief investigator also defends the 
study’s independence: “The SCOT trial is 
creating vital research capacity. It is entirely 
run by the University of Dundee, with no 
pharmaceutical company involvement in 
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any of our meetings. As such, mention of 
the Association of the British Pharmaceutical 
(ABPI) Code of Practice, which governs how 
drugs are commercially promoted to doctors 
by industry, is entirely inappropriate.”
Clause 19.1 of the code indicates that meet-
ings with clear educational content should 
be held at appropriate venues, conducive 
to the main purpose of the meeting. Lav-
ish, extravagant, or deluxe venues must not 
be used and companies should avoid using 
venues that are renowned for their entertain-
ment facilities. As a guide, the ABPI asks 
the industry to apply the question, “would 
you and your company be willing to have 
these arrangements generally known?” when 
determining whether the arrangements for 
any meeting are acceptable.
A spokesperson for Pfizer supported 
 Professor MacDonald in his position that the 
ABPI code did not apply to the  Gleneagles 
meeting: “All meetings organised by Pfizer 
or on our behalf are conducted to the high-
est standards of compliance with the ABPI 
code of practice. The SCOT study is an 
investigator driven research project led by 
 Professor Tom MacDonald of the  University 
of  Dundee, which is the sponsor of the clini-
cal trial. Pfizer has provided financial support 
to the study, but it is managed and operated 
independently of Pfizer. This meeting was 
not organised by Pfizer or on Pfizer’s behalf 
and it was solely the initiative and responsi-
bility of Professor MacDonald and the Uni-
versity of Dundee.”
Des Spence is from No Free Lunch UK, an 
organisation campaigning for a public regis-
ter of all hospitality and payments received 
by health professionals. He said: “This is 
 obviously not how patients for trials should 
be recruited. Doctors should be encouraged 
to recruit in a trial because they think it’s 
a good thing and will be beneficial for the 
patient. There are loads of ways they could 
go about recruiting for trials—they could go 
to health centres, have lunch meetings, for 
example—Gleneagles would seem inappro-
priate to most people. I would also question 
whether the overnight stay is necessary. Most 
doctors live in the central belt of Scotland 
and could drive through for the meeting in 
the morning.”
Yoon Loke, a co-convenor of the Cochrane 
Adverse Effects Methods Group and senior 
lecturer in clinical pharmacology at the 
 University of East Anglia, also has reserva-
tions: “Like all academic research projects 
with external funding, Pfizer has agreed 
to provide a certain sum of money to pay 
for the trial, and this will include costs of 
recruitment and investigators’ meetings—in 
 Gleneagles for this particular study. The 
money has been given to Dundee, but the 
source is still commercial.”
He thinks there are cheaper ways to con-
duct research in the public interest: “My col-
leagues and I currently have UK  Medical 
Research Council (MRC) funding for a 
project. When we applied for the money, 
we put down a sum of £1000 for meetings, 
and the MRC agreed to it. The last meeting 
for 12 researchers cost us roughly £300—we 
had sandwiches in a small hotel right next to 
Peterborough railway station.”
There are lavish meetings and frugal—
usually tax payer funded—ones, he says. 
“Tom MacDonald was only able to hold it 
at Gleneagles because money was coming 
from Pfizer. There would be no chance of 
Dundee University agreeing to pay for such 
a meeting from university funds.”
Appropriate design?
Dr Yoke, who specialises in developing meth-
ods for evaluating data on adverse effects, is 
also concerned about the trial’s design: “The 
patients all undergo a run-in phase before 
randomisation where they take celecoxib for 
two weeks prior to being allowed to take full 
part in the trial.3 What is the effect of this 
run-in phase? In my opinion, all the people 
who suffer side effects from celecoxib will 
drop out in the first two weeks, thus ensuring 
that the only people who continue in the trial 
will be those who do well with celecoxib. I 
have strong concerns about this type of study 
design as I don’t believe that the safety data 
would be as valid as with other ones.”
Robert M Elashoff, professor of biostatis-
tics and biomathematics at the University 
of  California, who specialises in clinical tri-
als design and analysis, agrees: “I think the 
effect of the run-in is to remove patients with 
unfavorable cardiovascular or gastrointestinal 
response. Those with side effects to celecoxib 
will be out of the study.
“Using a run-in with so many studies with 
celecoxib completed is silly. SCOT should be 
revised and the run-in deleted.”
A spokesperson for Pfizer said: “The 
SCOT study is an investigator driven research 
project . . . While Pfizer has provided finan-
cial support to the study, it is managed and 
operated independently of Pfizer. Therefore, 
the study sponsors should be contacted for a 
response to questions relating to the conduct 
of this study.”
“We found if we rented out a room 
somewhere during the week, 
doctors weren’t coming. But they 
are coming if we set up meetings 
at the weekend at Gleneagles” 
tom MacDonald
the trial is designed to compare  
the cardiovascular safety of the      
cyclo-oxygenase-2 (cOX-2)  
inhibitor celecoxib with that  
of other non-steroidal  
anti-inflammatory drugs (NsaiDs)
Pfizer has provided financial 
support to the study, but it 
is managed and operated 
independently of Pfizer
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The University of Dundee has declined 
to comment on these specific criticisms 
of the trial design but has released the full 
 protocol after a request under the Freedom 
of  Information Act. The document provides 
a rationale behind choices of study design: 
“The trial identifies chronic NSAID users in 
the population who were not taking ‘coxib’ 
[COX-2] drugs. These subjects have demon-
strated tolerance to NSAIDs. Switching of 
drug therapy to celecoxib as would happen to 
50% of subjects if ran-
domization occurred 
without an open label 
phase was thought to 
introduce a bias in that 
subjects would be more 
likely to tolerate their 
previous drug than the 
new one. For this rea-
son the open label phase allows those who 
have relatively similar tolerability and efficacy 
to both  therapies prior to randomization.”
The document explains that at the end of 
the run-in period, “Subjects who have taken 
at least one dose of celecoxib and who do 
not express a strong preference for either 
their previous treatment or celecoxib will be 
eligible for randomisation. Preference will 
be determined by the patient response to a 
questionnaire.”
Transparency
The trial has been registered on  ClinicalTrials.
gov so that the data can be used in the US.3 
The register encourages transparency in clini-
cal research by providing free access to infor-
mation about a trial’s funding, sponsorship, 
methodology, intervention, and research 
question.5 Its policy is consistent with US law 
and does not require the listing of collabora-
tors or funders if they are not considered the 
sponsor.6
There is no mention of Pfizer in the SCOT 
trial registration form.3 This isn’t a legal 
requirement, but Deborah Zarin, director 
of ClinicalTrials.gov, said that it may be a 
problem for other agencies: “It is up to the 
registrant and whomever enforces the other 
policies to ensure compliance. We don’t 
enforce their policies, but they have chosen 
to use our site as the mechanism for comply-
ing with their laws.”
A spokesperson for the International 
 Committee of Medical Journal Editors 
(ICMJE) said: “As stated in the ICMJE pol-
icy,7 funding source or sponsor is a required 
field for registration. Without this informa-
tion, the ICMJE would consider registration 
 insufficient.”
A spokesperson for Pfizer said: “Pfizer 
considers investigator driven research to be 
important in advancing disease treatments 
and consequently improving the lives of 
patients. Pfizer encourages all investigators 
to disclose information on research they 
are conducting; however, there is no formal 
requirement for them to do so.”
The University of Dundee has not 
 commented on why it chose to leave out the 
funding source from the clinical register.
David Miller, pro-
fessor of sociology at 
Strathclyde Univer-
sity, has also raised 
 concerns that the 
SCOT website  (www.
scottrial.co.uk) doesn’t 
mention funding from 
Pfizer—a fact also miss-
ing from some news pieces announcing the 
study.8-10 “ Neglecting to mention the financial 
sponsor of the research is deceptive,”  he says. 
“On the other hand the recruitment of doc-
tors via entertainment in five star luxury also 
appears to be ethically questionable.”
Howard Brody, director of the Institute for 
the Medical Humanities at the University of 
Texas Medical Branch, specialises in  ethical 
issues in primary care and professional integ-
rity in clinical research. He added: “The ‘pur-
pose’ of the study in the trial register reads 
more like a press release promoting celecoxib 
than a statement of today’s science. The 
notion that other NSAIDs pose a significant 
cardiovascular risk, comparable to that of 
COX-2 drugs, is a very dubious claim. This 
certainly makes me worried that the informa-
tion to be presented to research subjects will 
sound more like a marketing ploy and less 
like an assessment of the science.”
The participant information sheet pre-
sented to potential research subjects states 
that “one NSAID which appears to be at 
least as safe as most NSAIDs and may be 
safer than some is celecoxib.” The docu-
ment highlights that “there have also been 
a number of recent studies of this group of 
drugs [COX-2s] some of which have sug-
gested there may be a link between these 
newer drugs and increased heart disease and 
strokes. For Celebrex [celecoxib], this evi-
dence is not conclusive and there have been 
many studies that have shown no increased 
risk of heart disease and strokes.” It points 
to a recent meta-analysis suggesting that car-
diovascular effects for celecoxib are similar 
to those of other NSAIDs and states “there 
is also evidence that older NSAIDs have 
 cardiovascular effects.”
Professor MacDonald insists: “This isn’t a 
commercially viable trial for Pfizer. It’s not 
going to help their business model. They’re 
doing this because they have to fill a regula-
tory EMEA commitment.”
The health regulator has been monitor-
ing COX-2 inhibitors since 2004, when 
refecoxib was withdrawn because of a risk of 
 thrombotic cardiovascular events and ques-
tions were raised regarding the cardiovascular 
safety of other COX-2 inhibitors.11
As part of the EMEA’s December 2005 
decision to keep celecoxib on the  market, 
it recommended a long term study to inves-
tigate its safety relative to non-selective 
NSAIDs.
An EMEA spokesperson said: “You cannot 
force anyone to conduct clinical trials, but if 
a company wants its product to stay on the 
market then we need to be convinced that it 
should be there. It is in Pfizer’s commercial 
interest to do it.”
Professor MacDonald insists it is “Scot-
tish Government policy to promote research 
in primary care,” and the trial is “fully 
endorsed by the chief medical officer, the 
chief pharmaceutical officer and the chief 
scientist for  Scotland [and] uses methodol-
ogy which hopefully will allow similar types 
of  medicines research to be done more easily 
in the future.”
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